# DAFNA Capital Management LLC 13F Q2 2026: $524 million

DAFNA Capital Management LLC reported $524 million in 13F securities across 88 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Revolution Medicines Inc at $105 million, 20.1% of the reported value. Since Q1 2026 it opened 17 new positions and exited 12.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $524,358,409
- Positions: 88
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1389933
- Form 13F file number: 028-12327
- CRD number: 129053
- Business address: 10990 Wilshire Boulevard Suite 1400, Los Angeles, CA 90024
- SEC filing: [0001389933-26-000006](https://www.sec.gov/Archives/edgar/data/1389933/000138993326000006/0001389933-26-000006-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/dafna-capital-management-llc-129053)

## Top 25 holdings by value

The largest of 88 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155x100) | COM | 562,630 | $105.4 million | -18,048 |
| [SPDR Series Trust](https://specstream.ai/data/institutional-holders/spdr-series-trust-78464a870) | ST STR SP BIOT | 196,505 | $31.1 million | -122,000 |
| [Compass Pathways PLC](https://specstream.ai/data/institutional-holders/compass-pathways-plc-20451w101) | SPONSORED ADS | 2,011,952 | $28.5 million | -406,930 |
| [Stereotaxis Inc](https://specstream.ai/data/institutional-holders/stereotaxis-inc-85916j409) | COM NEW | 13,680,554 | $23.5 million | No change |
| [Nektar Therapeutics](https://specstream.ai/data/institutional-holders/nektar-therapeutics-640268306) | COM NEW | 318,380 | $22.2 million | +153,202 |
| [Denali Therapeutics Inc](https://specstream.ai/data/institutional-holders/denali-therapeutics-inc-24823r105) | COM | 739,014 | $19 million | +420,514 |
| [Ideaya Biosciences Inc](https://specstream.ai/data/institutional-holders/ideaya-biosciences-inc-45166a102) | COM | 497,240 | $18.5 million | +20,500 |
| [Atricure Inc](https://specstream.ai/data/institutional-holders/atricure-inc-04963c209) | COM | 597,431 | $16.7 million | No change |
| [Xenon Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/xenon-pharmaceuticals-inc-98420n105) | COM | 250,772 | $15.1 million | No change |
| [Cytokinetics Inc](https://specstream.ai/data/institutional-holders/cytokinetics-inc-23282w605) | COM NEW | 171,998 | $14.7 million | -45,499 |
| [Arcus Biosciences Inc](https://specstream.ai/data/institutional-holders/arcus-biosciences-inc-03969f109) | COM | 441,829 | $13.6 million | -2,000 |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 48,469 | $12.9 million | New |
| [Neurocrine Biosciences Inc](https://specstream.ai/data/institutional-holders/neurocrine-biosciences-inc-64125c109) | COM | 57,769 | $9.7 million | -12,846 |
| [Axogen Inc](https://specstream.ai/data/institutional-holders/axogen-inc-05463x106) | COM | 208,960 | $9.7 million | -41,000 |
| [Insulet Corp](https://specstream.ai/data/institutional-holders/insulet-corp-45784p101) | COM | 61,870 | $9.4 million | +51,000 |
| [Edgewise Therapeutics Inc](https://specstream.ai/data/institutional-holders/edgewise-therapeutics-inc-28036f105) | COM | 226,819 | $9.2 million | +114,583 |
| [Bicara Therapeutics Inc](https://specstream.ai/data/institutional-holders/bicara-therapeutics-inc-055477103) | COM | 284,955 | $8.5 million | -136,778 |
| [Ishares TR](https://specstream.ai/data/institutional-holders/ishares-tr-464287556) | ISHARES BIOTECH | 42,595 | $8.1 million | -19,500 |
| [Syndax Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/syndax-pharmaceuticals-inc-87164f105) | COM | 335,255 | $7.3 million | +117,900 |
| [Maplight Therapeutics Inc](https://specstream.ai/data/institutional-holders/maplight-therapeutics-inc-56565p103) | COM | 171,006 | $6.1 million | No change |
| [Larimar Therapeutics Inc](https://specstream.ai/data/institutional-holders/larimar-therapeutics-inc-517125100) | COM | 2,008,164 | $6.1 million | -21,000 |
| [Century Therapeutics Inc](https://specstream.ai/data/institutional-holders/century-therapeutics-inc-15673t100) | COM | 2,400,458 | $5.9 million | -33,895 |
| [Dexcom Inc](https://specstream.ai/data/institutional-holders/dexcom-inc-252131107) | COM | 86,279 | $5.8 million | No change |
| [Immunovant Inc](https://specstream.ai/data/institutional-holders/immunovant-inc-45258j102) | COM | 149,524 | $5.8 million | -1,000 |
| [Inogen Inc](https://specstream.ai/data/institutional-holders/inogen-inc-45780l104) | COM | 845,179 | $5.5 million | No change |

## New positions in Q2 2026

17 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 48,469 | $12.9 million |
| [Kymera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kymera-therapeutics-inc-501575104) | COM | 27,000 | $3.1 million |
| [Adlai Nortye LTD](https://specstream.ai/data/institutional-holders/adlai-nortye-ltd-00704r109) | SPONSORED ADS | 239,553 | $2.8 million |
| [Nervgen Pharma Corp](https://specstream.ai/data/institutional-holders/nervgen-pharma-corp-64082x203) | COM | 1,050,000 | $2.2 million |
| [Atrium Therapeutics Inc](https://specstream.ai/data/institutional-holders/atrium-therapeutics-inc-04965n104) | COM | 128,000 | $1.7 million |
| [Eupraxia Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/eupraxia-pharmaceuticals-inc-29842p105) | COM | 225,600 | $1.5 million |
| [Design Therapeutics Inc](https://specstream.ai/data/institutional-holders/design-therapeutics-inc-25056l103) | COM | 102,600 | $1.5 million |
| [Corbus Pharmaceuticals Hldgs](https://specstream.ai/data/institutional-holders/corbus-pharmaceuticals-hldgs-21833p301) | COM NEW | 107,773 | $1 million |
| [Seaport Therapeutics Inc](https://specstream.ai/data/institutional-holders/seaport-therapeutics-inc-81221k108) | COMMON STOCK | 32,400 | $703,728 |
| [Artiva Biotherapeutics Inc](https://specstream.ai/data/institutional-holders/artiva-biotherapeutics-inc-04317a107) | COM | 67,101 | $650,880 |
| [Scynexis Inc](https://specstream.ai/data/institutional-holders/scynexis-inc-811292309) | COM | 135,868 | $552,983 |
| [Editas Medicine Inc](https://specstream.ai/data/institutional-holders/editas-medicine-inc-28106w103) | COM | 170,470 | $552,323 |
| [Q32 Bio Inc](https://specstream.ai/data/institutional-holders/q32-bio-inc-746964105) | COM | 32,896 | $419,095 |
| [Nuvectis Pharma Inc](https://specstream.ai/data/institutional-holders/nuvectis-pharma-inc-67080t108) | COM | 20,000 | $367,800 |
| [Tenaya Therapeutics Inc](https://specstream.ai/data/institutional-holders/tenaya-therapeutics-inc-87990a106) | COM | 300,000 | $221,730 |
| [Engene Therapeutics Inc](https://specstream.ai/data/institutional-holders/engene-therapeutics-inc-29286x101) | COM | 74,650 | $129,145 |
| [Kardigan Inc](https://specstream.ai/data/institutional-holders/kardigan-inc-485925101) | COM | 5,000 | $119,250 |

## Positions exited in Q2 2026

12 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Day One Biopharmaceuticals I | COM | 978,463 | $21 million |
| Ascendis Pharma A/S | NOTE 2.250% 4/0 (principal) | 4,000,000 | $5.9 million |
| Kalvista Pharmaceuticals Inc | COM | 267,402 | $5.4 million |
| Ascendis Pharma A/S | SPONSORED ADR | 23,177 | $5.3 million |
| [Fulcrum Therapeutics Inc](https://specstream.ai/data/institutional-holders/fulcrum-therapeutics-inc-359616109) | COM | 205,000 | $1.6 million |
| Engene Holdings Inc | COM | 187,353 | $1.3 million |
| Scynexis Inc | COM NEW | 1,086,956 | $996,630 |
| [Oric Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/oric-pharmaceuticals-inc-68622p109) | COM | 98,724 | $945,460 |
| [Zenas Biopharma Inc](https://specstream.ai/data/institutional-holders/zenas-biopharma-inc-98937l105) | COM | 42,500 | $830,875 |
| [Newamsterdam Pharma Company](https://specstream.ai/data/institutional-holders/newamsterdam-pharma-company-n62509109) | ORDINARY SHARES | 20,000 | $640,200 |
| [Karyopharm Therapeutics Inc](https://specstream.ai/data/institutional-holders/karyopharm-therapeutics-inc-48576u205) | COM NEW | 45,800 | $255,106 |
| [Neumora Therapeutics Inc.](https://specstream.ai/data/institutional-holders/neumora-therapeutics-inc-640979100) | COM | 70,000 | $136,500 |

## Also on SpecStream

- [DAFNA Capital Management LLC Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1389933/000138993326000006/0001389933-26-000006-index.htm)
- [DAFNA Capital Management LLC investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/dafna-capital-management-llc-129053)
- [Largest 13F filers in California](https://specstream.ai/data/institutional-holdings/state/california)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Los Angeles, California

- [Medical research institutes in Los Angeles, California](https://specstream.ai/data/businesses/medical-research-institutes/los-angeles-california-united-states)
- [Public schools in Los Angeles, California](https://specstream.ai/data/businesses/public-schools/los-angeles-california-united-states)
- [Women's health clinics in Los Angeles, California](https://specstream.ai/data/businesses/womens-health-clinics/los-angeles-california-united-states)
- [Cocktail bars in Los Angeles, California](https://specstream.ai/data/businesses/cocktail-bars/los-angeles-california-united-states)
- [Furniture manufacturers in Los Angeles, California](https://specstream.ai/data/businesses/furniture-manufacturers/los-angeles-california-united-states)
- [Medical supply stores in Los Angeles, California](https://specstream.ai/data/businesses/medical-supply-stores/los-angeles-california-united-states)
